Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Gets Mixed Results On Renvela Powder Formulation

This article was originally published in The Pink Sheet Daily

Executive Summary

An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.

You may also be interested in...



Genzyme Renal Division President John Butler: An Interview With “The Pink Sheet” DAILY

Butler speaks with the DAILY about the Renvela launch, plans for a next-generation phosphate binder and other candidates in the biotech’s renal pipeline.

Genzyme Renal Division President John Butler: An Interview With “The Pink Sheet” DAILY

Butler speaks with the DAILY about the Renvela launch, plans for a next-generation phosphate binder and other candidates in the biotech’s renal pipeline.

Genzyme’s Renvela Approved For Kidney Disease Patients On Dialysis

Filing for predialysis indication is on track for first half of 2008 after “positive” outcome of FDA Cardio-Renal Advisory Committee meeting, Genzyme Renal President Butler tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS066193

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel